What is TNGX's current stock price?

TNGX (Tango Therapeutics, Inc.) is currently trading at $20.24 with a market cap of $2.35B.

What sector is Tango Therapeutics, Inc. in?

Tango Therapeutics, Inc. (TNGX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TNGX a good stock to buy?

Analysts have a Buy consensus on TNGX with a price target of $34.83. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TNGX Tango Therapeutics, Inc.

Healthcare

$20.24-6.38%ClosedMarket Cap: $2.35B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

7.42

P/S

41.26

EV/EBITDA

-19.66

DCF Value

$-13.53

FCF Yield

-6.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

97.3%

Operating Margin

-206.2%

Net Margin

-188.2%

ROE

-41.5%

ROA

-24.6%

ROIC

-27.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-45.5M	$—
Q4 null	$0.00	$-38.7M	$—
FY null	$62.4M	$-101.6M	$—
Q3 null	$53.8M	$15.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$34.83

Target (Median)

$31.50

Target Range

$24.00 - $55.00

1 Strong Buy10 Buy3 Hold0 Sell0 Strong Sell

Piper SandlerNeutral

2026-05-15

MizuhoOutperform

2026-05-15

Leerink PartnersOutperform

2026-05-14

WedbushOutperform

2026-05-14

JefferiesHold

2026-05-14

Trading Activity

Insider Trades

View All

Gall Matthewofficer: Chief Financial Officer

SellTue May 05

Gall Matthewofficer: Chief Financial Officer

SellTue May 05

Crystal Adamofficer: President, R&D

SellTue May 05

Crystal Adamofficer: President, R&D

SellTue May 05

Crystal Adamofficer: President, R&D

SellTue May 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.22

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Peers

KOD